Ann: Change of Director's Interest Notice x 4, page-5

The sp decline has definitely not been good. Nor has been the loooong delay between the first and second phases of the clinical trials, nor the lack of news which caused the big decline earlier this year on the lack of perceived progress and news. However, Epichem is growing and PPL1/MPL looks like shaping up into something good and all along they've been putting their own money into the shares even as they slid down, they've got lots of skin in the company, which tells you what they really think. It's high risk of course, so you'd been mad to bet your house on it, on the other hand it could turn out to be bottler. Shares like this are not for the faint hearted.